Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PTIX 
Protagenic Therapeutics (PTIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/12/2025: PTIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.46% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.88M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 0.38 | 52 Weeks Range 1.83 - 14.28 | Updated Date 11/12/2025 |
52 Weeks Range 1.83 - 14.28 | Updated Date 11/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.13 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -189.6% | Return on Equity (TTM) -512.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3560547 | Price to Sales(TTM) - |
Enterprise Value 3560547 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.64 | Shares Outstanding 1927898 | Shares Floating 491613 |
Shares Outstanding 1927898 | Shares Floating 491613 | ||
Percent Insiders 11.21 | Percent Institutions 10.11 |
Upturn AI SWOT
Protagenic Therapeutics
Company Overview
History and Background
As of October 26, 2023, Protagenic Therapeutics does not appear to be a publicly traded company with a well-documented history available in standard financial databases. Information is extremely limited, suggesting it may be a private or very new entity.
Core Business Areas
Leadership and Structure
Due to the lack of publicly available information, details about Protagenic Therapeutics's leadership team and organizational structure are unavailable.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
Without defined products or services, it's impossible to determine the specific industry or market in which Protagenic Therapeutics operates.
Positioning
Insufficient information prevents assessing the company's market positioning or competitive advantages.
Total Addressable Market (TAM)
TAM cannot be determined due to lack of information about the company.
Upturn SWOT Analysis
Strengths
Weaknesses
- Lack of publicly available information
- Unclear business model
- Unknown financial status
Opportunities
- Potential for growth if products and services are developed
- Opportunity to establish a market presence
Threats
- Competition from established companies
- Funding challenges
- Regulatory hurdles (depending on industry)
Competitors and Market Share
Key Competitors
Competitive Landscape
Cannot assess competitive advantages or disadvantages.
Growth Trajectory and Initiatives
Historical Growth: No historical growth data is available.
Future Projections: No future projections can be made.
Recent Initiatives: No information on recent strategic initiatives is available.
Summary
Given the very limited publicly available information, it's difficult to assess the viability of Protagenic Therapeutics. The lack of financial history and business specifics raises significant questions. Substantial further investigation would be needed to make any informed assessment. If this company is very new or private, the data does not exist to make an evaluation.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Public domain web search results
Disclaimers:
The information provided is based on limited publicly available data and may not be accurate or complete. This analysis is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protagenic Therapeutics
Exchange NASDAQ | Headquaters Santa Barbara, CA, United States | ||
IPO Launch date 2016-01-05 | President, CEO & Director Mr. Barrett Evans | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://phytanix.com |
Full time employees - | Website https://phytanix.com | ||
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.